RUNX1 Dosage in Development and Cancer
Michael Lie-a-ling1,6, Renaud Mevel1,6, Rahima Patel1, Karen Blyth2,3, Esther Baena4, Valerie Kouskoff5,*, and Georges Lacaud1,*
1Cancer Research UK Stem Cell Biology Group, Cancer Research UK Manchester Institute, The University of Manchester, Macclesfield, SK10 4TG, UK, 2Cancer Research UK Beatson Institute, Glasgow, G61 1BD, UK, 3Institute of Cancer Sciences, University of Glasgow, Glasgow, G61 1QH, UK, 4Cancer Research UK Prostate Oncobiology Group, Cancer Research UK Manchester Institute, The University of Manchester, Macclesfield, SK10 4TG, UK, 5Division of Developmental Biology & Medicine, The University of Manchester, Manchester, M13 9PT, UK, 6These authors contributed equally to this work.
Received December 2, 2019; Accepted December 4, 2019.; Published online January 24, 2020.
© Korean Society for Molecular and Cellular Biology. All rights reserved.

ABSTRACT
The transcription factor RUNX1 first came to prominence due to its involvement in the t(8;21) translocation in acute myeloid leukemia (AML). Since this discovery, RUNX1 has been shown to play important roles not only in leukemia but also in the ontogeny of the normal hematopoietic system. Although it is currently still challenging to fully assess the different parameters regulating RUNX1 dosage, it has become clear that the dose of RUNX1 can greatly affect both leukemia and normal hematopoietic development. It is also becoming evident that varying levels of RUNX1 expression can be used as markers of tumor progression not only in the hematopoietic system, but also in non-hematopoietic cancers. Here, we provide an overview of the current knowledge of the effects of RUNX1 dosage in normal development of both hematopoietic and epithelial tissues and their associated cancers.
Keywords: development; dosage; hematopoiesis; runx1; tumorigenesis


Current Issue

31 January 2020 Volume 43,
Number 1, pp. 1~95

This Article


Cited By Articles
  • CrossRef (0)

Social Network Service
Services

Indexed in

  • Science Central
  • CrossMark